OakChart

Trevi Therapeutics Inc

TRVIHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

14.81-0.10 (-0.64%)
2026-11-12 02:23 CET
Market cap
2,110.78 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-60.76 USD m
Free cash flow, TTM
-61.69 USD m
EPS diluted, TTM
-0.40
P/E
-
Compare

Price

TRVI against its 20, 50 and 200-day averages
2050200beatearnings
12.5015.0017.5020.004.2M8.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TRVIclose 14.8220-day 13.3750-day 14.17200-day 14.4914.8252w high

26.7% under the 52-week high of 20.22 on 17 Jul 2026. 52-week low 9.82 on 19 Feb 2026. Last 15 sessions, 25.5% high to low

Volume 0.78× normal · the line is the 50-bar volume average

Profile

TRVI
52-week range, 48% of the way up
9.8220.22

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

IndexRUT
Employees34
IPOMay 07, 2019
Beta1.12
ATR, 14d0.84
Rel volume0.78
Short float16.35%
Insider own27.67%
Inst own83.26%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.11B
Enterprise Value1.81B
Income-60.76M
Sales0.00M
Book/sh2.12
Cash/sh2.10
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees34
IPOMay 07, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B6.97
P/C7.05
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio38.86
Current Ratio38.86
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.40
EPS next Y-0.66
EPS next Q-0.15
EPS this Y-52.08%
EPS next Y-34.93%
EPS next 5Y-
EPS past 3/5Y11.11% 29.44%
Sales past 3/5Y- -
EPS Y/Y TTM-6.57%
Sales Y/Y TTM-
EPS Q/Q-65.19%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.1.29% -

Ownership

Insider Own27.67%
Insider Trans-0.10%
Inst Own83.26%
Inst Trans10.77%
ROA-23.82%
ROE-24.67%
ROIC-20.06%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2010.79%
SMA504.56%
SMA2002.23%
Trades-

Technical

Shs Outstand142.53M
Shs Float103.11M
Short Float16.35%
Short Ratio8.67
Short Interest16.86M
52W High20.22 -26.73%
52W Low9.82 50.87%
Volatility8.85% 5.75%
ATR (14)0.84
RSI (14)58.65
Beta1.12
Rel Volume0.78
Avg Volume1.94M
Volume1,518,661

Performance

Perf Week5.93%
Perf Month20.55%
Perf Quarter-18.37%
Perf Half Y-2.98%
Perf YTD18.33%
Perf Year22.44%
Perf 3Y1030.92%
Perf 5Y1155.51%
Perf 10Y-
Recom1.00
Target Price29.50
Prev Close14.91
Price14.81
Change %-0.64%

Analyst ratings

latest 10 of 18
DateActionAnalystRating changeTargetImplied
Jul 21, 2026InitiatedBBMO Capital MarketsOutperform$36+143.0%
Nov 13, 2025InitiatedLLeerink PartnersOutperform$13-12.3%
Aug 21, 2025InitiatedMMorgan StanleyOverweight$18+21.5%
Jul 01, 2025InitiatedCCantor FitzgeraldOverweight$25+68.7%
May 28, 2025InitiatedHH.C. WainwrightBuy$21+41.7%
Mar 10, 2025UpgradeRRaymond JamesOutperform → Strong Buy$9 → $29+95.7%
Mar 10, 2025ReiteratedNNeedhamBuy$8 → $25+68.7%
Dec 12, 2024ReiteratedHH.C. WainwrightBuy$6 → $7.50-49.4%
Sep 09, 2024ResumedLLeerink PartnersOutperform$6 → $7-52.8%
Aug 30, 2024InitiatedRRaymond JamesOutperform$9-39.3%

Peers

Mkt cap
TickerCompanyMkt cap
SVRASavara Inc1.10B
GSKGSK Plc ADR101.43B
PLRXPliant Therapeutics Inc48.15M
INSMInsmed Inc26.49B
MLYSMineralys Therapeutics Inc1.43B
MRKMerck & Co Inc362.83B
SEPNSepterna Inc2.31B
TVRDTvardi Therapeutics Inc17.88M
UPBUpstream Bio Inc175.27M
UTHRUnited Therapeutics Corp25.37B

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Heffernan Michael ThomasDirectorSep 15 '26Option Exercise3.1939,473126,10327,403Sep 17 04:55 PM
Heffernan Michael ThomasDirectorSep 15 '26Sale15.0939,473595,8066,351Sep 17 04:55 PM
MICHAEL HEFFERNANDirectorSep 15 '26Proposed Sale15.8939,473627,226Sep 15 04:42 PM
Galletta ChristopherSee RemarksDec 02 '25Option Exercise0.514,2252,15926,095Dec 03 04:16 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200
  • Trevi Therapeutics Matches Loss Estimates As FDA Alignment And A Cleared Field Offset Slipping Timelines And A Narrower Runway (Earnings Whispers) +6.84%
  • Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Trevi's Third-Quarter Report Hinges On OCEAN-2 Start And Countdown To LAKE Interim Look (Earnings Whispers)
  • Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026 (GlobeNewswire)
  • Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference (GlobeNewswire) +6.71%
  • Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting (GlobeNewswire)
  • Top 4 Healthcare Stocks Backed by Raymond James Analysts (Investing.com)
  • Trevi Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
  • Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 (GlobeNewswire)
  • Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ... (GuruFocus.com)
  • Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 (GlobeNewswire)
  • Trevi Therapeutics to Participate in Upcoming August Conferences (GlobeNewswire)
  • Trevi Therapeutics Announces Upcoming June and July Event Schedule (GlobeNewswire) +6.30%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.130-0.132-0.1300.000.0012
2026Q22026-08-06-0.110-0.110-0.1140.000.0012
2026Q12026-05-05-0.090-0.076-0.0910.000.0012
2025Q42026-03-17-0.060-0.097-0.0570.000.0012
2025Q32025-11-13-0.080-0.098-0.0810.000.0012
2025Q22025-08-07-0.090-0.104-0.0940.000.0011
2025Q12025-05-08-0.090-0.123-0.0880.000.0010
2024Q42025-03-18-0.110-0.128-0.1080.000.0011
2024Q32024-11-06-0.130-0.120-0.1310.000.0010
2024Q22024-08-08-0.120-0.109-0.1220.000.007
2024Q12024-05-07-0.110-0.087-0.1100.000.005
2023Q42024-03-20-0.080-0.092-0.0790.000.006
2023Q32023-11-09-0.080-0.092-0.0780.000.006
2023Q22023-08-10-0.070-0.085-0.0720.000.006
2023Q12023-05-11-0.060-0.074-0.0650.000.006
2022Q42023-03-16-0.060-0.106-0.0560.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.340-1.963-2.2800.000.00
2020FY-1.820-1.733-1.8140.000.00
2021FY-1.490-1.495-1.4860.000.00
2022FY-0.450-0.542-0.4520.000.00
2023FY-0.290-0.305-0.2940.000.00
2024FY-0.470-0.507-0.4700.000.00
2025FY-0.320-0.364-0.3200.000.00
2026FY--0.487--0.00
2027FY--0.657--0.00
2028FY--0.762--0.00
2029FY--0.742--62.04
2030FY--0.144--229.52

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-106000.000.000.00
2026Q4S2026-11-096000.000.000.00
2026Q4S2026-08-076000.000.000.00
2026Q4S2026-06-266000.000.000.00
2026Q4S2026-05-067000.000.000.00
2026Q4S2026-03-287000.000.000.00
2026Q4S2026-03-188000.000.000.00
2026Q4S2025-12-187000.000.000.00
2026Q4S2025-11-176000.000.000.00
2026Q4S2025-11-165000.000.000.00
2026Q4S2025-11-146000.000.000.00
2026Q4S2025-11-115000.000.000.00
2026Q4S2025-11-105000.000.000.00
2026Q4S2025-11-095000.000.000.00

Estimate history

EPS, annual-0.703-1.439-2.28-1.814-1.486-0.452-0.294-0.47-0.317-0.3957
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.131-0.108-0.088-0.094-0.081-0.057-0.091-0.114-0.134
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual17.83517.77217.83518.54728.50659.94368.28493.603128.306142.529
Period201720182019202020212022202320242025MRQ
Shares, quarterly75.45493.60399.893121.776128.215128.306128.411142.421142.529
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.140.130.150.120.040.050.050.040.02
Gross Profit-0.14-0.13-0.15-0.12-0.04-0.05-0.05-0.04-0.02
Selling, General and Administrative Excl. Other69.9949.2051.3833.8029.9032.4332.4426.6118.39
Research and Development50.3533.4839.3823.6819.8722.9822.3319.3414.07
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-70.13-49.33-51.52-33.92-29.94-32.48-32.49-26.64-18.41
Interest Expense--0.000.391.161.200.460.000.17
Unusual Expense0.000.000.000.000.15-0.080.010.212.24
Net Income Before Taxes-60.83-42.82-47.94-29.10-29.22-33.96-32.78-26.07-20.67
Income Taxes-0.07-0.06-0.03-0.03-0.07-0.02-0.02-0.02-0.12
Consolidated Net Income-60.76-42.76-47.91-29.07-29.15-33.94-32.76-26.05-20.55
Net Income From Continuing Operations-60.76-42.76-47.91-29.07-29.15-33.94-32.76-26.05-20.55
Net Income-60.76-42.76-47.91-29.07-29.15-33.94-32.76-26.75-25.58
EPS (Recurring)-0.38-0.32-0.47-0.29-0.45-1.49-1.81-2.27-1.35
EPS (Basic, Before Extraordinaries)-0.40-0.32-0.47-0.29-0.45-1.49-1.81-2.28-1.44
EPS (Diluted)-0.40-0.32-0.47-0.29-0.45-1.49-1.81-2.28-1.44
EBITDA-69.99-49.20-51.38-33.80-29.90-32.43-32.44-26.61-18.39
Non-Operating Income (Expense)9.306.503.595.222.03-0.360.180.790.16
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.044.102.831.781.841.861.760.820.50
Shares Outstanding142.53128.3193.6068.2859.9428.5118.5517.8317.77
Market Capitalization2,110.782,110.78368.1985.57115.6520.2244.4866.8866.88

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.030.030.030.040.040.040.04
Gross Profit-0.04-0.03-0.03-0.03-0.04-0.04-0.04-0.04
Selling, General and Administrative Excl. Other24.4520.4814.8810.1913.8813.6811.4312.21
Research and Development19.0615.159.946.1910.099.397.819.33
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-24.49-20.51-14.91-10.22-13.92-13.72-11.47-12.24
Interest Expense0.000.000.00---0.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-21.47-17.82-13.21-8.33-11.82-12.32-10.35-11.40
Income Taxes-0.02-0.02-0.02-0.02-0.01-0.02-0.010.02
Consolidated Net Income-21.45-17.80-13.19-8.32-11.80-12.30-10.34-11.41
Net Income From Continuing Operations-21.45-17.80-13.19-8.32-11.80-12.30-10.34-11.41
Net Income-21.45-17.80-13.19-8.32-11.80-12.30-10.34-11.41
EPS (Recurring)-0.13-0.11-0.09-0.06-0.08-0.09-0.09-0.11
EPS (Basic, Before Extraordinaries)-0.13-0.11-0.09-0.06-0.08-0.09-0.09-0.11
EPS (Diluted)-0.13-0.11-0.09-0.06-0.08-0.09-0.09-0.11
EBITDA-24.45-20.48-14.88-10.19-13.88-13.68-11.43-12.21
Non-Operating Income (Expense)3.022.691.701.892.101.401.120.84
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.662.581.731.070.981.090.950.72
Shares Outstanding142.53142.42128.41128.31128.22121.7899.8993.60
Market Capitalization2,110.782,647.931,531.781,605.441,114.26651.72608.13368.19

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments188.26107.6282.97120.5136.8345.0057.317.2022.02
Short Term Receivables0.990.530.000.00-0.270.560.180.05
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.411.274.582.111.131.001.681.440.09
Total Current Assets191.66109.4387.55122.6237.9646.2759.558.8222.16
Net Property, Plant & Equipment0.851.231.560.190.180.330.430.150.01
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets----0.000.000.000.000.00
Deferred Tax Assets0.18--------
Other Assets0.930.240.300.200.330.530.021.550.05
Total Assets193.62110.9089.40123.0238.4847.1360.0010.5322.23
Short Term Debt Incl. Current Port. of LT Debt0.310.280.317.036.070.110.100.005.29
Accounts Payable3.913.411.812.862.852.021.600.600.54
Other Current Liabilities5.536.813.713.523.813.433.502.071.30
Total Current Liabilities9.7510.515.8213.4012.725.555.202.687.12
Long Term Debt0.450.751.032.158.6814.290.261.100.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.18--------
Other Liabilities0.000.000.000.000.000.000.000.510.33
Total Liabilities10.3811.266.8615.5621.4019.855.464.287.45
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00115.7499.21
Common Equity183.2499.6482.55107.4617.0727.2854.55-109.49-84.43
Total Shareholders Equity183.2499.6482.55107.4617.0727.2854.556.2514.78
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity183.2499.6482.55107.4617.0727.2854.556.2514.78
Total Liabilities & Stockholders Equity193.62110.9089.40123.0238.4847.1360.0010.5322.23
Book Value Per Share1.431.061.211.790.601.473.06-6.16-4.73
Tangible Book Value Per Share1.431.061.211.790.601.473.06-6.16-4.73
Full-Time Employees342625252422171515
Price to Book Ratio6.975.270.951.021.311.651.231.10-
Return on Assets-28.08-47.84-27.37-36.10-79.29-61.15-73.87-125.45-83.95
Return on Equity-30.23-52.59-30.59-46.82-153.03-80.07-85.70-195.42-
Return on Invested Capital-23.28-47.72-34.78-26.60-131.80-78.79-47.53-279.75-87.02
Quick Ratio19.6610.4115.039.152.988.3311.453.303.11
Current Ratio19.6610.4115.039.152.988.3311.453.303.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-60.76-42.76-47.91-29.07-29.15-33.94-32.76-26.05-20.55
Depreciation0.140.140.150.120.040.050.050.040.02
Other Funds (Non Cash)8.204.022.681.082.173.442.651.342.80
Funds from Operations-52.41-38.60-45.08-27.86-26.94-30.45-30.06-24.67-17.72
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-9.02-3.496.83-3.85-1.231.511.061.58-0.60
Cash from Operating Activities-61.44-42.09-38.26-31.71-28.18-28.95-29.00-23.09-18.32
Capital Expenditures-0.25-0.01-0.04-0.14-0.160.00-0.03-0.01-0.16
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-132.61-94.09-21.4959.56-107.210.000.000.000.00
Purchase of Investments-263.93-170.66-98.46-9.93-126.220.000.000.000.00
Sale Or Maturity of Investments131.3276.5776.9769.5019.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-132.86-94.11-21.5359.43-107.370.00-0.03-0.01-0.16
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock164.55120.3061.61-0.12117.1613.34-0.3373.89-1.52
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock164.55120.3061.61-0.12117.1613.34-0.3373.89-1.52
Proceedsfrom Stock Options172.73118.2261.22-0.19105.2413.34-0.3673.85-1.53
Issuance or Reduction of Debt, Net0.000.00-0.13-9.41-5.83-0.0713.920.005.15
Change in Long Term Debt0.000.00-0.13-9.41-5.83-0.0713.920.00-5.34
Issuance of Long Term Debt0.000.000.000.000.000.0014.000.000.00
Reduction of Long Term Debt0.000.00-0.13-9.41-5.83-0.07-0.080.00-5.34
Net Financing Active Other Cash Flow0.720.720.001.710.007.503.13-0.680.00
Other Financing Activities Uses0.000.000.000.000.000.000.00-0.680.00
Cash from Financing Activities165.28121.0161.48-7.91111.3120.7716.7273.213.63
Net Change in Cash-29.02-15.181.7019.81-24.24-8.17-12.3150.11-14.85
Free Cash Flow-61.69-42.10-38.29-31.85-28.33-28.95-29.03-23.10-18.48
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments299.41318.87171.78188.26194.93203.88
Short Term Receivables1.801.601.100.990.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.595.243.242.413.373.34
Total Current Assets305.80325.70176.12191.66198.30207.23
Net Property, Plant & Equipment0.810.880.880.850.951.04
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---0.18--
Other Assets4.203.942.610.930.100.07
Total Assets310.81330.52179.61193.62199.36208.34
Short Term Debt Incl. Current Port. of LT Debt0.340.330.320.310.300.29
Accounts Payable1.513.102.213.912.712.97
Other Current Liabilities6.025.314.585.536.045.98
Total Current Liabilities7.878.747.129.759.049.24
Long Term Debt0.190.280.360.450.530.60
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.18--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities8.069.017.4810.389.579.85
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity302.76321.51172.13183.24189.79198.49
Total Shareholders Equity302.76321.51172.13183.24189.79198.49
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity302.76321.51172.13183.24189.79198.49
Total Liabilities & Stockholders Equity310.81330.52179.61193.62199.36208.34
Book Value Per Share2.122.261.341.431.481.63
Tangible Book Value Per Share2.122.261.341.431.481.63
Full-Time Employees---34--
Price to Book Ratio6.9713.918.358.465.615.49
Return on Assets-23.82-18.97-31.83-28.08-34.19-33.53
Return on Equity-24.67-19.66-33.59-30.23-36.87-35.74
Return on Invested Capital-7.08-5.53-7.65-4.53-6.20-6.18
Quick Ratio38.8637.2824.7519.6621.9322.42
Current Ratio38.8637.2824.7519.6621.9322.42

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.45-17.80-13.19-8.32-11.80-12.30
Depreciation0.040.030.030.030.040.04
Other Funds (Non Cash)2.552.861.860.931.051.11
Funds from Operations-18.86-14.91-11.29-7.36-10.71-11.15
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.83-2.52-5.40-0.27-0.171.05
Cash from Operating Activities-19.69-17.43-16.69-7.63-10.88-10.10
Capital Expenditures-0.03-0.12-0.100.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-7.15-111.9117.07-30.61-50.93-2.61
Purchase of Investments-47.49-153.56-8.48-54.40-71.61-17.11
Sale Or Maturity of Investments40.3441.6525.5523.7920.6814.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-7.18-112.0416.96-30.61-50.94-2.61
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.41164.360.22-0.441.63110.39
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.41164.360.22-0.441.63110.39
Proceedsfrom Stock Options0.00162.640.0010.09108.72-0.37
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.720.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.41164.360.220.281.63110.39
Net Change in Cash-26.4534.890.50-37.95-60.1997.68
Free Cash Flow-19.71-17.55-16.79-7.63--

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.36%16.9M103.1M1.94M
2026-10-1515.53%16.0M103.1M2.09M
2026-09-3014.21%14.6M103.1M1.93M
2026-09-1511.71%12.1M103.1M2.20M
2026-08-3112.47%12.0M96.4M2.12M
2026-08-1413.14%12.7M96.4M2.06M
2026-07-3113.15%13.1M100.0M2.06M
2026-07-1513.66%12.7M92.6M2.02M
2026-06-3014.98%13.9M92.6M1.77M
2026-06-1515.50%14.4M92.6M1.43M
2026-05-2914.66%13.6M92.6M1.50M
2026-05-1514.35%13.3M92.6M1.52M
2026-04-3016.77%15.3M91.2M1.49M
2026-04-1517.93%16.1M90.0M1.36M
2026-03-3118.55%15.3M82.5M1.39M
2026-03-1319.94%16.4M82.5M1.43M
2026-02-2720.42%16.8M82.3M1.65M
2026-02-1319.44%16.0M82.3M1.79M
2026-01-3018.51%15.5M83.8M1.83M
2026-01-1518.57%15.6M83.8M1.80M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call7.005.809.700.007.9200.000.000.901-0.1300.004
call8.004.808.700.006.6390.000.000.884-0.1240.005
call9.003.807.700.005.9530.000.000.862-0.1220.005
call10.002.806.703.205.15750.000.000.837-0.1160.006
call11.001.805.702.864.3770.000.000.807-0.1060.006
call12.000.904.800.753.9135800.000.770-0.1000.007
call13.000.403.900.003.4020.000.000.719-0.0880.008
call14.000.152.351.131.1627623.000.644-0.0690.009
call15.000.300.500.850.6311040.000.504-0.0550.009
call16.000.001.150.501.0242030.000.383-0.0620.009
call17.000.000.700.301.3311.000.000.289-0.0600.008
call18.000.000.950.001.5940.000.000.255-0.0670.007
call19.000.002.150.961.8278.000.000.232-0.0730.007
call20.000.000.950.002.0370.000.000.216-0.0780.007
call21.000.002.150.602.2282,5000.000.203-0.0820.007
call22.000.002.000.002.4040.000.000.193-0.0860.006
call23.000.002.150.003.1830.000.000.265-0.1340.008
call24.000.002.150.003.3460.000.000.257-0.1390.008
call25.000.002.150.003.4990.000.000.250-0.1430.007
call26.000.002.150.003.6430.000.000.244-0.1470.007
call27.000.002.150.003.7790.000.000.239-0.1510.007
call30.000.002.150.004.1460.000.000.226-0.1600.007
put7.000.002.100.005.7170.000.00-0.099-0.1290.004
put8.000.002.100.004.9210.000.00-0.117-0.1260.005
put9.000.002.150.004.1550.000.00-0.140-0.1180.005
put10.000.002.150.003.6030.000.00-0.163-0.1150.006
put11.000.002.150.103.0362,9660.00-0.193-0.1080.006
put12.000.002.150.552.50350.000.00-0.230-0.0990.007
put13.000.000.950.011.9920.000.00-0.281-0.0870.008
put14.000.000.950.501.48251.000.00-0.356-0.0680.009
put15.000.001.550.001.5840.000.00-0.496-0.0540.009
put16.000.003.600.003.1460.000.00-0.617-0.0610.009
put17.000.454.500.003.3890.000.00-0.711-0.0580.008
put18.001.405.300.003.4780.000.00-0.745-0.0650.007
put19.002.356.300.003.7530.000.00-0.768-0.0710.007
put20.004.406.800.003.4420.000.00-0.784-0.0760.007
put21.004.308.200.004.1170.000.00-0.797-0.0800.007
put22.005.309.200.004.3250.000.00-0.807-0.0840.006
put23.006.3010.200.004.5190.000.00-0.816-0.0870.006
put24.007.3011.200.004.6990.000.00-0.823-0.0900.006
put25.008.3012.100.004.7530.000.00-0.829-0.0920.006
put26.009.3013.200.005.0270.000.00-0.834-0.0950.006
put27.0010.3014.200.005.1770.000.00-0.839-0.0970.006
put30.0013.3017.200.005.5820.000.00-0.850-0.1030.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-27SCHEDULE 13G/ASEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06SCHEDULE 13G/ASEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-05-07SCHEDULE 13D/ASEC
2026-05-06SCHEDULE 13G/ASEC
2026-05-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-05-05SEC
2026-04-21DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-21SEC
2026-04-21ARSAnnual report to security holders. 2025-12-31SEC
2026-04-21DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-17424B5SEC
2026-04-178-KCurrent report2026-04-16SEC
2026-04-16424B5SEC
2026-04-10PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-10SEC
2026-03-27SCHEDULE 13G/ASEC
2026-03-1710-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-178-KCurrent report2026-03-17SEC
2026-03-098-KCurrent report2026-03-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900595.81K1
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC9.57%
NEA Management Company, LLC9.31%
BlackRock, Inc.7.86%
Frazier Life Sciences Management, L.P.7.00%
WELLINGTON MANAGEMENT GROUP LLP4.00%
VANGUARD CAPITAL MANAGEMENT LLC3.90%
Vivo Capital, LLC3.59%
Woodline Partners LP2.87%
Assenagon Asset Management S.A.2.48%
Vestal Point Capital, LP2.18%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.85%
iShares Russell 2000 ETF1.94%
Eventide Healthcare & Life Sciences Fund1.87%
Select Biotechnology Portfolio1.67%
Fidelity Small Cap Growth Fund1.37%
VANGUARD EXTENDED MARKET INDEX FUND0.95%
Fidelity Small Cap Index Fund0.83%
Fidelity Growth Company Fund0.73%
AB Small Cap Growth Portfolio0.73%
Fidelity Small Cap Growth K6 Fund0.70%

OakChart. TRVI. Cached 15 minutes.